Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.
3.

Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.

Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, Smith LL.

Toxicol Appl Pharmacol. 1995 Jul;133(1):12-9.

PMID:
7597701
4.
5.

Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione.

Molchanov S, Gryff-Keller A.

Acta Biochim Pol. 2009;56(3):447-54. Epub 2009 Jul 21.

6.

Spectroscopic and computational studies of NTBC bound to the non-heme iron enzyme (4-hydroxyphenyl)pyruvate dioxygenase: active site contributions to drug inhibition.

Neidig ML, Decker A, Kavana M, Moran GR, Solomon EI.

Biochem Biophys Res Commun. 2005 Dec 9;338(1):206-14. Epub 2005 Sep 9.

PMID:
16197918
7.

Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.

Hanauske-Abel HM, Popowicz A, Remotti H, Newfield RS, Levy J.

J Pediatr Gastroenterol Nutr. 2002 Jul;35(1):73-8.

PMID:
12142814
8.

Mutations in the 4-hydroxyphenylpyruvic acid dioxygenase gene are responsible for tyrosinemia type III and hawkinsinuria.

Tomoeda K, Awata H, Matsuura T, Matsuda I, Ploechl E, Milovac T, Boneh A, Scott CR, Danks DM, Endo F.

Mol Genet Metab. 2000 Nov;71(3):506-10.

PMID:
11073718
9.

Evidence for the mechanism of hydroxylation by 4-hydroxyphenylpyruvate dioxygenase and hydroxymandelate synthase from intermediate partitioning in active site variants.

Shah DD, Conrad JA, Heinz B, Brownlee JM, Moran GR.

Biochemistry. 2011 Sep 6;50(35):7694-704. doi: 10.1021/bi2009344. Epub 2011 Aug 16.

PMID:
21815644
10.

Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse.

Lock EA, Gaskin P, Ellis MK, McLean Provan W, Robinson M, Smith LL.

Toxicology. 2000 Apr 3;144(1-3):179-87.

PMID:
10781886
11.

4-Hydroxyphenylpyruvate dioxygenase.

Moran GR.

Arch Biochem Biophys. 2005 Jan 1;433(1):117-28. Review.

PMID:
15581571
14.

Manifestation of hawkinsinuria in a patient compound heterozygous for hawkinsinuria and tyrosinemia III.

Item CB, Mihalek I, Lichtarge O, Jalan A, Vodopiutz J, Muhl A, Bodamer OA.

Mol Genet Metab. 2007 Aug;91(4):379-83. Epub 2007 Jun 7.

PMID:
17560158
15.

4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target.

Yang DY.

Drug News Perspect. 2003 Oct;16(8):493-6. Review.

PMID:
14668946
16.

Identification of a novel 4-hydroxyphenylpyruvate dioxygenase from the soil metagenome.

Lee CM, Yeo YS, Lee JH, Kim SJ, Kim JB, Han NS, Koo BS, Yoon SH.

Biochem Biophys Res Commun. 2008 May 30;370(2):322-6. doi: 10.1016/j.bbrc.2008.03.102. Epub 2008 Mar 31.

PMID:
18381065
17.

Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1-3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat.

Lock EA, Gaskin P, Ellis MK, Provan WM, Robinson M, Smith LL, Prisbylla MP, Mutter LC.

Toxicol Appl Pharmacol. 1996 Dec;141(2):439-47.

PMID:
8975769
18.
20.

Synthesis and bioevaluation of pyrazole-benzimidazolone hybrids as novel human 4-Hydroxyphenylpyruvate dioxygenase inhibitors.

Xu YL, Lin HY, Ruan X, Yang SG, Hao GF, Yang WC, Yang GF.

Eur J Med Chem. 2015 Mar 6;92:427-38. doi: 10.1016/j.ejmech.2015.01.018. Epub 2015 Jan 10.

PMID:
25590863

Supplemental Content

Support Center